We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
New York-based drug discovery company Volastra Therapeutics has signed a deal with Bristol Myers Squibb (BMS) potentially worth up to $1.1 billion to create new medicines for undisclosed targets. Read More
AstraZeneca (AZ) has agreed to pay Chugai Pharmaceutical $775 million to resolve allegations that AZ’s rare disease immunotherapy, Ultomiris (ravulizumab), infringed on the Tokyo-based company’s patents. Read More
Novartis has agreed to manufacture Carisma Therapeutics’ new line of bioengineered macrophages which, like CAR-T cells, can be reprogrammed to attack patient-specific tumors. Read More
Accused of stealing trade secrets through a former employee of AbbVie’s, Alvotech will pay royalties to AbbVie for licensing its patents in July 2023. Read More